Experienced in Gaucher Disease

Dr. Maria L. Escolar

Pediatrics
1450 Raleigh Rd, Suite 100, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 4 Trials
33 Years of Experience
Experienced in Gaucher Disease
1450 Raleigh Rd, Suite 100, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maria Escolar is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Escolar has been practicing medicine for over 33 years and is rated as an Experienced provider by MediFind in the treatment of Gaucher Disease. Her top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).

Her clinical research consists of co-authoring 74 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Gaucher Disease.

Specialties
Pediatrics
Licenses
Pediatrics in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1450 Raleigh Rd, Suite 100, Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Enrollment Status: Recruiting
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drugs: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Study Phase: Phase 2
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Enrollment Status: Recruiting
Publish Date: July 17, 2025
Intervention Type: Drug, Biological
Study Drug: ABO-102
Study Phase: Phase 2/Phase 3
Longitudinal Study of Neurodegenerative Disorders
Longitudinal Study of Neurodegenerative Disorders
Enrollment Status: Recruiting
Publish Date: March 07, 2025
Intervention Type: Biological, Other
A Prospective Outcomes Study of Pediatric and Adult Patients with Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation with a Reduced-Intensity Conditioning Regimen (PRO-RIC)
A Prospective Outcomes Study of Pediatric and Adult Patients with Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation with a Reduced-Intensity Conditioning Regimen (PRO-RIC)
Enrollment Status: Recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: DNL310
Study Phase: Phase 1/Phase 2
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)
A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Biological
Study Drug: FBX-101
Study Phase: Phase 1/Phase 2
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Other
The Natural History of Metachromatic Leukodystrophy
The Natural History of Metachromatic Leukodystrophy
Enrollment Status: Withdrawn
Publish Date: May 30, 2024
A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients With Middle and Advanced Phases of MPS IIIA Disease
A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients With Middle and Advanced Phases of MPS IIIA Disease
Enrollment Status: Terminated
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: ABO-102
Study Phase: Phase 1/Phase 2
A Retrospective and Cross-sectional Study to Evaluate Neurodevelopmental Status in Pediatric Subjects With Severe Mucopolysaccharidosis Type II (Hunter Syndrome)
A Retrospective and Cross-sectional Study to Evaluate Neurodevelopmental Status in Pediatric Subjects With Severe Mucopolysaccharidosis Type II (Hunter Syndrome)
Enrollment Status: Completed
Publish Date: April 26, 2022
Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

74 Total Publications

MBOAT7 encephalopathy: Characterizing the neurology and epileptology.
MBOAT7 encephalopathy: Characterizing the neurology and epileptology.
Journal: Epilepsia
Published: December 03, 2024
Similar Doctors
Elite in Gaucher Disease
Dr. Priya S. Kishnani
Pediatrics
Elite in Gaucher Disease
Dr. Priya S. Kishnani
Pediatrics

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (8.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Priya Kishnani is a Pediatrics provider in Durham, North Carolina. Dr. Kishnani is rated as an Elite provider by MediFind in the treatment of Gaucher Disease. Her top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Hypophosphatasia (HPP), Glycogen Storage Disease Type 9, and Splenectomy. Dr. Kishnani is currently accepting new patients.

Advanced in Gaucher Disease
Dr. Chad Haldeman
Medical Genetics | Pediatrics
Advanced in Gaucher Disease
Dr. Chad Haldeman
Medical Genetics | Pediatrics

The Moses H Cone Memorial Hospital Operating Corporation

1200 N Elm St, 
Greensboro, NC 
 (45.3 miles away)
336-574-7771
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chad Haldeman is a Medical Genetics specialist and a Pediatrics provider in Greensboro, North Carolina. Dr. Haldeman is rated as an Advanced provider by MediFind in the treatment of Gaucher Disease. His top areas of expertise are Fabry Disease, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy with Subcortical Cysts, and Danon Disease.

Experienced in Gaucher Disease
Dr. Joseph Muenzer
Pediatrics
Experienced in Gaucher Disease
Dr. Joseph Muenzer
Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
 (2.1 miles away)
919-966-4131
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Muenzer is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Muenzer is rated as a Distinguished provider by MediFind in the treatment of Gaucher Disease. His top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). Dr. Muenzer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Escolar's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile